{Reference Type}: Duplicate Publication
{Title}: Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
{Author}: Menter A;Cordoro KM;Davis DMR;Kroshinsky D;Paller AS;Armstrong AW;Connor C;Elewski BE;Gelfand JM;Gordon KB;Gottlieb AB;Kaplan DH;Kavanaugh A;Kiselica M;Kivelevitch D;Korman NJ;Lebwohl M;Leonardi CL;Lichten J;Lim HW;Mehta NN;Parra SL;Pathy AL;Farley Prater EA;Rupani RN;Siegel M;Stoff B;Strober BE;Wong EB;Wu JJ;Hariharan V;Elmets CA;
{Journal}: J Am Acad Dermatol
{Volume}: 82
{Issue}: 1
{Year}: Jan 2020
{Factor}: 15.487
{DOI}: 10.1016/j.jaad.2019.08.049
{Abstract}: Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence. This guideline addresses important clinical questions that arise in psoriasis management and provides evidence-based recommendations. Attention will be given to pediatric patients with psoriasis, recognizing the unique physiology, pharmacokinetics, and patient-parent-provider interactions of patients younger than 18 years old. The topics reviewed here mirror those discussed in the adult guideline sections, excluding those topics that are irrelevant to, or lack sufficient information for, pediatric patients.